Successful treatment of primary, metastatic, and recurrent cancer disease is primarily based on early and precise diagnosis. Challenges in meeting these criteria are:

  • The need for visible tumor for tissue biopsy.
  • limited predictive value of histopathological and molecular classifications; and
  • missing biomarkers. Liquid biopsies are non invasive methods to diagnose cancer disease, predict and monitor disease progression, and finally to improve patient selection for established treatment strategies.

IGnomix liquid biopsy test is simple blood test helps in early detection of cancer and guides clinicians to offer a personalized treatment for metastatic patients.